Goldline Pharmaceutical Ltd.
BBSE:GLPL29.98
INR
-2.02
(-6.31%)
ISIN
INE1CLW01015
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Semi-annual Revenue
INR
•
in mil. unless spec.Semi-annual Earnings Per Share
INR
•
in mil. unless spec.Semi-annual Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Amol Laxmikant Mujumdar
- Full Time Employees
- 126
- Sector
- Distribution services
- Industry
- Medical distributors
- Address
- Nagpur India
- IPO Date
- May 19, 2026
- Website
- goldlinepharma.in
- Similar Companies
- Business
- Goldline Pharmaceutical Limited is an India-based pharmaceutical marketing and distribution company that provides a comprehensive range of branded pharmaceutical formulations and healthcare products across diverse therapeutic categories. Founded in 2004 and headquartered in Nagpur, Maharashtra, the company operates an asset-light business model, utilizing third-party contract manufacturers to produce its proprietary healthcare portfolio. Goldline Pharmaceutical markets over 200 formulations organized across five specialized business divisions: Goldline Pharma, which supplies oral solid dosages, analgesics, anti-infectives, anti-inflammatory drugs, gastrointestinal agents, and urology medications to general physicians, ENT specialists, and orthopedic surgeons; Goldline Cardinal, offering cardiovascular treatments, anti-diabetic formulations, lipid-lowering agents, and endocrine therapies; Goldline Aayushman, providing pediatric suspensions, drops, antibiotics, and pediatric nutritional supplements; Goldline InLife, delivering critical care injectables, intravenous formulations, and surgical products to intensivists and hospital care centers; and Goldline Wellness, offering supportive therapies, antioxidant supplements, and specialized quality-of-life products for oncology and chronic care patients. The company's product dosage forms comprise tablets; hard and soft gelatin capsules; oral syrups and suspensions; injectable solutions; topical ointments, creams, and gels; and dietary powders. Geographically, Goldline Pharmaceutical distributes its products across nine Indian states, including Maharashtra, Chhattisgarh, Madhya Pradesh, Odisha, Tamil Nadu, Rajasthan, Jharkhand, Goa, and Bihar. In recent developments, the company converted to a public limited company and completed its Initial Public Offering on the BSE SME platform in May 2026, raising capital to fund working capital requirements, settle existing debt, and accelerate the expansion of its distribution network and product offerings across domestic markets.